Timolol maleate 0.5% microdrops delivered with the Nanodropper Adaptor met three noninferiority endpoints in lowering IOP compared with conventional timolol drops, according to a study.
“We anticipate the Nanodropper system with timolol will revolutionize glaucoma treatment by offering a more efficient, cost-effective and safer delivery method,” Jennifer S. Steger, PhD, lead author of the study published in Ophthalmology, told Healio. “This innovation has the potential to streamline patient care and improve outcomes in glaucoma management.”
The prospective,